NEW YORK – Ideaya Biosciences said on Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
New Jersey Senate Bill 3098 would require health insurance plans to cover biomarker testing for the diagnosis, treatment, and management of a patient's disease.
A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...
The variant, present in the NFKB1 gene and common in the Aymara community, could help guide treatment decisions, researchers ...
Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...
SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...
In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have ...
Lymphoma patients better tolerated the CAR T-cell therapy manufactured on site at the Sheba Medical Center than they did the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback